Olanzapine
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
- Olanzapine
- Olanzapine: From Schizophrenia/Bipolar I Disorder to Benign Paroxysmal Torticollis of Infancy
Olanzapine: From Schizophrenia/Bipolar I Disorder to Benign Paroxysmal Torticollis of Infancy
One-Sentence Summary
Olanzapine is an atypical antipsychotic (5-HT2A/D2 receptor antagonist) originally used for schizophrenia and bipolar I disorder. The TxGNN model’s top-ranked prediction for this drug is Benign Paroxysmal Torticollis of Infancy, but this association is currently supported by 0 clinical trials and 0 publications, and the evidence pack’s own mechanistic review flags it as a likely statistical artifact rather than a biologically grounded signal.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Schizophrenia and bipolar I disorder (atypical antipsychotic; TFDA/ARTG licence data not available — see Market Information below) |
| Predicted New Indication | Benign Paroxysmal Torticollis of Infancy |
| TxGNN Prediction Score | 99.54% |
| Evidence Level | L5 |
| Australia Market Status | Not marketed |
| Number of ARTG Entries | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data for Olanzapine is not available in this evidence pack (flagged as a High-severity data gap). Based on other information within the pack, Olanzapine is known to act primarily through D2 dopamine and 5-HT2A serotonin receptor antagonism, a mechanism well established in the treatment of psychotic and mood disorders.
For this specific prediction, however, the evidence pack’s own mechanistic rationale is explicit that no pharmacological link exists: benign paroxysmal torticollis of infancy is generally regarded as a migraine-variant channelopathy, and it has no known relationship to Olanzapine’s D2/5-HT2A antagonism. The reviewer notes this is most likely a statistical association produced by the TxGNN model rather than a mechanism-driven signal.
Because no clinical trials, no literature, and no coherent mechanistic story support this candidate, it should be treated as a low-confidence, exploratory hit only.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Australia Market Information
Olanzapine has no ARTG entries in this evidence pack (market status: Not marketed, 0 licences on record). No product, dosage form, or approved-indication data is available to summarise.
Safety Considerations
Please refer to the TGA-approved Product Information (PI) for safety information. (TFDA warnings/contraindications and a formal DDI search were both attempted but returned no data — this is flagged in the evidence pack as a Blocking data gap for safety review.)
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked TxGNN prediction (benign paroxysmal torticollis of infancy) has no supporting clinical trials or literature, and the pack’s own mechanistic review characterises it as a statistical artifact rather than a genuine biological signal. Combined with the absence of Australian market registration and a blocking gap in safety/PI data, there is currently no basis to advance this specific candidate.
To proceed, the following is needed:
- TFDA/TGA Product Information (warnings, contraindications) — currently a Blocking gap
- Confirmed mechanism of action detail from DrugBank — currently a High-severity gap
- Any independent evidence (preclinical or clinical) connecting Olanzapine to benign paroxysmal torticollis of infancy, none of which currently exists
Note: This same evidence pack contains other Olanzapine candidates with materially stronger evidence — notably neurotic depression and melancholia (both L2/S2, ~20 supporting publications each, consistent with the established olanzapine–fluoxetine combination used in treatment-resistant depression), and agoraphobia/dysthymic disorder (L3/S1). If repurposing evaluation continues, one of these better-substantiated candidates would be a more productive next target than the top TxGNN-ranked hit reported here.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.